Literature DB >> 22524468

Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma.

Adam S Kabaker1, Mitchell E Tublin, Yuri E Nikiforov, Michaele J Armstrong, Steven P Hodak, Michael T Stang, Kelly L McCoy, Sally E Carty, Linwah Yip.   

Abstract

BACKGROUND: Current American Thyroid Association (ATA) guidelines recommend routine cervical ultrasound (US) in thyroid nodule evaluation. Specific US characteristics can help diagnose papillary thyroid carcinoma (PTC). The aim of this blinded cohort study was to determine whether these specific US characteristics can also reliably detect the more aggressive variants of PTC that are often associated with the BRAF(V600E) mutation.
METHODS: After Institutional Review Board approval, we identified a cohort of patients from January 2007 to December 2009 with histologic PTC≥1 cm who had cervical US, initial thyroid surgery, and molecular testing for BRAF(V600E) on fine-needle aspiration biopsy or histology. Preoperative US images were evaluated by a single radiologist, who was blinded to BRAF status, for nodule size and the presence or absence of the following suspicious US features: taller-than-wide shape, ill-defined margins, hypoechogenicity, calcifications, noncystic composition, and absent halo.
RESULTS: BRAF-positivity was associated with most known suspicious US findings, including taller-than-wide shape (47% vs. 7%, p<0.001), ill-defined margins (42% vs. 9%, p<0.001), hypoechogenicity (83% vs. 36%, p<0.001), micro/macrocalcifications (87% vs. 24%, p<0.001), and absent halo (85% vs. 27%, p<0.001) but was not associated with noncystic composition. When ≥3 suspicious US features were present, BRAF-positivity was predicted with a positive predictive value of 82%. The absence of suspicious US features together with negative BRAF testing predicted PTC without extrathyroidal extension or lymph node metastasis (negative predictive value 88%).
CONCLUSIONS: With routine preoperative cervical US and molecular testing, a trained radiologist or surgeon can improve the preoperative characterization of PTC, potentially impacting risk stratification and initial surgical management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22524468      PMCID: PMC3358112          DOI: 10.1089/thy.2011.0274

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  22 in total

1.  American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules.

Authors:  H Gharib; E Papini; R Paschke; D S Duick; R Valcavi; L Hegedüs; P Vitti
Journal:  J Endocrinol Invest       Date:  2010       Impact factor: 4.256

2.  Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Authors:  Linwah Yip; Marina N Nikiforova; Sally E Carty; John H Yim; Michael T Stang; Mitchell J Tublin; Shane O Lebeau; Steven P Hodak; Jennifer B Ogilvie; Yuri E Nikiforov
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

3.  Ultrasonographic characteristics of thyroid nodules: prediction of malignancy.

Authors:  E Koike; S Noguchi; H Yamashita; T Murakami; A Ohshima; H Kawamoto; H Yamashita
Journal:  Arch Surg       Date:  2001-03

4.  Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.

Authors:  Enrico Papini; Rinaldo Guglielmi; Antonio Bianchini; Anna Crescenzi; Silvia Taccogna; Francesco Nardi; Claudio Panunzi; Roberta Rinaldi; Vincenzo Toscano; Claudio M Pacella
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

5.  BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

Authors:  Christine J O'Neill; Martyn Bullock; Angela Chou; Stan B Sidhu; Leigh W Delbridge; Bruce G Robinson; Anthony J Gill; Diana L Learoyd; Roderick Clifton-Bligh; Mark S Sywak
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

6.  Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction.

Authors:  Jiyoung Hwang; Jung Hee Shin; Boo-Kyung Han; Eun Young Ko; Seok Seon Kang; Jong-Won Kim; Jae Hoon Chung
Journal:  AJR Am J Roentgenol       Date:  2010-05       Impact factor: 3.959

7.  Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma.

Authors:  Jin Young Kwak; Eun-Kyung Kim; Woong Youn Chung; Hee Jung Moon; Min Jung Kim; Jong Rak Choi
Journal:  Radiology       Date:  2009-08-25       Impact factor: 11.105

Review 8.  Molecular diagnostics and predictors in thyroid cancer.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

Review 9.  Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations.

Authors:  Won-Jin Moon; Jung Hwan Baek; So Lyung Jung; Dong Wook Kim; Eun Kyung Kim; Ji Young Kim; Jin Young Kwak; Jeong Hyun Lee; Joon Hyung Lee; Young Hen Lee; Dong Gyu Na; Jeong Seon Park; Sun Won Park
Journal:  Korean J Radiol       Date:  2011-01-03       Impact factor: 3.500

Review 10.  The utility of BRAF testing in the management of papillary thyroid cancer.

Authors:  Adrienne L Melck; Linwah Yip; Sally E Carty
Journal:  Oncologist       Date:  2010-12-08
View more
  24 in total

1.  Suspicious ultrasound and clinicopathological features of papillary thyroid carcinoma predict the status of TERT promoter.

Authors:  Hui Shi; Le-Hang Guo; Yi-Feng Zhang; Hui-Jun Fu; Jia-Yi Zheng; Han-Xiang Wang; Chong-Ke Zhao; Hui-Xiong Xu
Journal:  Endocrine       Date:  2020-02-05       Impact factor: 3.633

2.  Radiomics Study of Thyroid Ultrasound for Predicting BRAF Mutation in Papillary Thyroid Carcinoma: Preliminary Results.

Authors:  M-R Kwon; J H Shin; H Park; H Cho; S Y Hahn; K W Park
Journal:  AJNR Am J Neuroradiol       Date:  2020-04       Impact factor: 3.825

3.  Prediction of thyroid extracapsular extension with cervical lymph node metastases (ECE-LN) by CEUS and BRAF expression in papillary thyroid carcinoma.

Authors:  Xi Wei; Ying Li; Sheng Zhang; Ming Gao
Journal:  Tumour Biol       Date:  2014-05-27

4.  All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer.

Authors:  Sarah C Oltmann; David F Schneider; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-09-19       Impact factor: 5.344

5.  Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.

Authors:  Martina Rossi; Mattia Buratto; Federico Tagliati; Roberta Rossi; Sabrina Lupo; Giorgio Trasforini; Giovanni Lanza; Paola Franceschetti; Stefania Bruni; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Thyroid       Date:  2014-11-24       Impact factor: 6.568

Review 6.  Molecular testing in the diagnosis of differentiated thyroid carcinomas.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Salvatore Ulisse; Enke Baldini; Riccardo Giannini; Paolo Miccoli; Alessandro Antonelli; Fulvio Basolo
Journal:  Gland Surg       Date:  2018-08

Review 7.  Thyroid nodules in pediatrics: which ones can be left alone, which ones must be investigated, when and how.

Authors:  Andrea Corrias; Alessandro Mussa
Journal:  J Clin Res Pediatr Endocrinol       Date:  2013

8.  A Case of simultaneous occurrence of Marine - Lenhart syndrome and a papillary thyroid microcarcinoma.

Authors:  Thomas Scherer; Evelyne Wohlschlaeger-Krenn; Michaela Bayerle-Eder; Christian Passler; Angelika Reiner-Concin; Michael Krebs; Alois Gessl
Journal:  BMC Endocr Disord       Date:  2013-05-08       Impact factor: 2.763

9.  Higher EU-TIRADS-Score Correlated with BRAF V600E Positivity in the Early Stage of Papillary Thyroid Carcinoma.

Authors:  Karolina Skubisz; Joanna Januszkiewicz-Caulier; Patrycja Cybula; Elwira Bakuła-Zalewska; Krzysztof Goryca; Agnieszka Paziewska; Filip Ambrożkiewicz; Kosma Woliński; Michał Mikula; Jerzy Ostrowski; Marek Dedecjus
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

10.  Can Suspicious Ultrasound Features Predict BRAFV600E Status in Papillary Thyroid Cancer?

Authors:  Helmi Khadra; Ahmed Deniwar; Khuzema Mohsin; Dominique Monlezun; Emad Kandil
Journal:  Eur Thyroid J       Date:  2018-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.